Cannabidiol
Total Payments
$2.6M
Transactions
712
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $1.2M | 146 | 0 |
| 2017 | $1.5M | 566 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.6M | 712 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder | INSYS Therapeutics Inc | $750,394 | 0 |
| Cannabidiol Treatment in Patient with early psychosis | INSYS Therapeutics Inc | $446,812 | 0 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | INSYS Therapeutics Inc | $425,715 | 0 |
| A Phase 1, Open-Label, Randomized, Single-Dose, Four-Treatment, Four-Sequence, Four-Period, Four-Way crossover Food Effect Study of Multiple Formulations of Cannabidiol Oral Solution in Healthy Subjects | INSYS Therapeutics Inc | $229,239 | 0 |
| Cannabidiol | INSYS Therapeutics Inc | $171,239 | 0 |
| Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures | INSYS Therapeutics Inc | $127,830 | 0 |
| A multicenter, open-label, flexible dose study to assess the long-term safety of pharmaceutical Cannabidiol Oral Solution as an adjunctive treatment for pediatric subjects with a treatment-resistant seizure disorder who complete INS011-14-029 or Part A of INS011-15-054 | INSYS Therapeutics Inc | $119,180 | 0 |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome | INSYS Therapeutics Inc | $106,442 | 0 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders | INSYS Therapeutics Inc | $78,023 | 0 |
| Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome | INSYS Therapeutics Inc | $57,698 | 0 |
| Open-label, flexible dose study to assess the long-term safety of pharmaceutical Cannabidiol Oral solution as an adjunctive treatment for pediatric and adult subjects with a treatment-resistant seizure disorder | INSYS Therapeutics Inc | $43,602 | 0 |
| An Expanded Access Program (EAP) to assess the long-term safety of pharmaceutical Cannabidiol Oral Solution as an adjunctive treatment for pediatric subjects with a treatment-resistant seizure disorder who complete INS011-14-030 | INSYS Therapeutics Inc | $25,954 | 0 |
| An Expanded Access IND treatment plan for patients with a treatment resistant seizure disorder taking Cannabidiol Oral Solution who have completed study INS011-14-030 (EA45201) | INSYS Therapeutics Inc | $16,195 | 0 |
| Single-Patient Emergency Use of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric and Adult Subjects with a Treatment-resistant Seizure Disorder | INSYS Therapeutics Inc | $12,458 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Patients with Prader-Willi Syndrome | INSYS Therapeutics Inc | $11,858 | 0 |
| A Mutlicenter,Open-label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients with Prader-Willi Syndrome | INSYS Therapeutics Inc | $1,833 | 0 |
Top Doctors Receiving Payments for Cannabidiol
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Miami, FL | $2.6M | 712 |
Ad
Manufacturing Companies
- INSYS Therapeutics Inc $2.6M
Product Information
- Type Drug
- Total Payments $2.6M
- Total Doctors 0
- Transactions 712
About Cannabidiol
Cannabidiol is a drug associated with $2.6M in payments to 0 healthcare providers, recorded across 712 transactions in the CMS Open Payments database. The primary manufacturer is INSYS Therapeutics Inc.
Payment data is available from 2017 to 2018. In 2018, $1.2M was paid across 146 transactions to 0 doctors.
The most common payment nature for Cannabidiol is "Unspecified" ($2.6M, 100.0% of total).
Cannabidiol is associated with 16 research studies, including "Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder" ($750,394).